002432 九安医疗
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入531,269-30.58%1,365,5892,592,1963,231,12526,315,361
减:营业总成本770,112-14.23%1,634,0941,884,2142,186,3117,434,730
    其中:营业成本170,654-34.06%493,971760,1981,176,5725,367,195
               财务费用141,778-742.90%(31,807)(6,631)(199,522)(209,149)
               资产减值损失(8,906)-15.98%(34,568)(53,479)(309,867)(321,559)
公允价值变动收益3,647,465397.19%2,113,543739,622309,288(326,401)
投资收益128,331-67.20%718,395712,471560,73893,483
    其中:对联营企业和合营企业的投资收益(910)2,754.94%(910)(1,990)--(1,266)
营业利润3,526,432259.44%2,535,3922,109,8021,613,49118,311,869
利润总额3,522,588259.07%2,527,2592,106,8701,580,34418,257,857
减:所得税费用448,376636.63%257,754306,828231,1121,773,763
净利润3,074,212234.09%2,269,5041,800,0421,349,23216,484,094
减:非控股权益3,989250,222.35%2,756131,31597,624453,925
股东净利润3,070,223233.66%2,266,7481,668,7271,251,60816,030,169

市场价值指针
每股收益 (元) *7.333248.39%5.2293.8142.81535.138
每股派息 (元) *----1.6500.2000.3002.500
每股净资产 (元) *49.6548.19%46.95742.07939.38140.357
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容